You are here: Industry Insights > Daiichi Sankyo

News List

FDA Grants Priority Review for Daiichi Sankyo's NDA for FLT3 Inhibitor Quizartinib americanpharmaceuticalreview
November 29, 2018
Daiichi Sankyo announced the U.S. Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) and granted Priority Review for quizartinib for the treatment....
Daiichi Sankyo in pursuit of Novartis’ Rydapt with next-generation FLT3 drug fiercebiotech
May 16, 2018
Novartis’ FLT3 inhibitor Rydapt was a much-welcomed addition to the armamentarium against acute myeloid leukemia when it was approved last year.
Daiichi Sankyo seeks approval for Diagnogreen biospectrumasia
February 26, 2018
Daiichi Sankyo Submits Application for Additional Indication and Dosage for DiagnogreenⓇ for Injection 25 mg in Japan
Daiichi Sankyo and Puma Biotech to assess combination cancer therapy pharmaceutical-technology
December 15, 2017
Daiichi Sankyo conducted a preclinical study with Puma Biotechnology and the Memorial Sloan Kettering Cancer Center to evaluate combination therapy with HER2 mutation / HER2-positive solid tumor therapy.
Vernalis, Daiichi Sankyo work together on new cancer targets pharmatimes
December 14, 2017
UK drugmaker Vernalis has signed a drug discovery deal with Daiichi Sankyo Co that aims to find new targets for potential cancer therapies.
Daiichi Sankyo announces TaNeDS Global 2018 collaborative drug discovery program worldpharmanews
September 27, 2017
Daiichi Sankyo Company, Limited today announced details of the application for its Take a New Challenge for Drug Discovery (TaNeDS) Global 2018
Daiichi Sankyo Terminates Agreement with Charleston Laboratories americanpharmaceuticalreview.
September 01, 2017
Daiichi Sankyo has elected to terminate its 2014 development and commercialization agreement with Charleston
Daiichi Sankyo Announces Positive Top-line Results from Phase 3 Clinical Trial Evaluating Mirogabali americanpharmaceuticalreview.
September 01, 2017
Daiichi Sankyo announced positive top-line results from REDUCER (an Asian, phase 3, multicenter, RandomizEd, Double-blind, placebo-controlled 14-week stUdy of mirogabalin in patients with diabetiC pEripheral neuRopathic pain, followed by a 52-week open-la
Daiichi Sankyo enters licencing agreement with Boston Pharmaceuticals for RET inhibitor for solid tu pharmaasia
September 01, 2017
Daiichi Sankyo grants Boston Pharmaceuticals worldwide rights for the research, development, manufacturing and commercialisation of DS-5010.
Daiichi Sankyo Enters Worldwide Licensing Agreement with Boston Pharmaceuticals americanpharmaceuticalreview
August 30, 2017
Daiichi Sankyo and Boston Pharmaceuticals have entered into a worldwide licensing agreement for Daiichi Sankyo's novel RET inhibitor, DS-5010.

Previous page 1 2 3 4 5 6 7 8 Next page